COVID-19: Important Therapy Considerations and Approaches in this Hour of Need.
Identifieur interne : 000273 ( Main/Exploration ); précédent : 000272; suivant : 000274COVID-19: Important Therapy Considerations and Approaches in this Hour of Need.
Auteurs : Thomas P. Lodise [États-Unis] ; Michael J. Rybak [États-Unis]Source :
- Pharmacotherapy [ 1875-9114 ] ; 2020.
Abstract
We are living in unprecedented times. While we had near pandemic events in the recent past with SARS (severe acute respiratory syndrome) and MERS (Middle East respiratory syndrome), we have never experienced anything like coronavirus (COVID-19), also known as SARS-CoV-2 infection, since the Spanish flu. In contrast to the Spanish flu where medical care was limited, we are equipped to combat COVID-19 but there is considerable work ahead with many uncertainties. At this critical time, we must come together as one united country and world to stop the spread and provide the best care possible for individuals who contract the virus and develop infection. A number of novel and repurposed therapies agents with activity against SARS-CoV-2 have been identified and most institutions have developed clinical pathways to operationalize their use in appropriate COVID-19 patients.1-3 However, optimal drug therapy decisions for those with moderate to severe COVID-19 infections are extremely challenging at this time as evidence is limited.
DOI: 10.1002/phar.2396
PubMed: 32267556
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000067
- to stream PubMed, to step Curation: 000067
- to stream PubMed, to step Checkpoint: 000280
- to stream Ncbi, to step Merge: 002724
- to stream Ncbi, to step Curation: 002724
- to stream Ncbi, to step Checkpoint: 002724
- to stream Main, to step Merge: 000276
- to stream Main, to step Curation: 000273
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">COVID-19: Important Therapy Considerations and Approaches in this Hour of Need.</title><author><name sortKey="Lodise, Thomas P" sort="Lodise, Thomas P" uniqKey="Lodise T" first="Thomas P" last="Lodise">Thomas P. Lodise</name><affiliation wicri:level="2"><nlm:affiliation>Albany College of Pharmacy and Health Sciences, Albany, NY, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Albany College of Pharmacy and Health Sciences, Albany, NY</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Rybak, Michael J" sort="Rybak, Michael J" uniqKey="Rybak M" first="Michael J" last="Rybak">Michael J. Rybak</name><affiliation wicri:level="2"><nlm:affiliation>Wayne State University, Detroit, MI, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Wayne State University, Detroit, MI</wicri:regionArea><placeName><region type="state">Michigan</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32267556</idno><idno type="pmid">32267556</idno><idno type="doi">10.1002/phar.2396</idno><idno type="wicri:Area/PubMed/Corpus">000067</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000067</idno><idno type="wicri:Area/PubMed/Curation">000067</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000067</idno><idno type="wicri:Area/PubMed/Checkpoint">000280</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000280</idno><idno type="wicri:Area/Ncbi/Merge">002724</idno><idno type="wicri:Area/Ncbi/Curation">002724</idno><idno type="wicri:Area/Ncbi/Checkpoint">002724</idno><idno type="wicri:Area/Main/Merge">000276</idno><idno type="wicri:Area/Main/Curation">000273</idno><idno type="wicri:Area/Main/Exploration">000273</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">COVID-19: Important Therapy Considerations and Approaches in this Hour of Need.</title><author><name sortKey="Lodise, Thomas P" sort="Lodise, Thomas P" uniqKey="Lodise T" first="Thomas P" last="Lodise">Thomas P. Lodise</name><affiliation wicri:level="2"><nlm:affiliation>Albany College of Pharmacy and Health Sciences, Albany, NY, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Albany College of Pharmacy and Health Sciences, Albany, NY</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Rybak, Michael J" sort="Rybak, Michael J" uniqKey="Rybak M" first="Michael J" last="Rybak">Michael J. Rybak</name><affiliation wicri:level="2"><nlm:affiliation>Wayne State University, Detroit, MI, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Wayne State University, Detroit, MI</wicri:regionArea><placeName><region type="state">Michigan</region></placeName></affiliation></author></analytic><series><title level="j">Pharmacotherapy</title><idno type="eISSN">1875-9114</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We are living in unprecedented times. While we had near pandemic events in the recent past with SARS (severe acute respiratory syndrome) and MERS (Middle East respiratory syndrome), we have never experienced anything like coronavirus (COVID-19), also known as SARS-CoV-2 infection, since the Spanish flu. In contrast to the Spanish flu where medical care was limited, we are equipped to combat COVID-19 but there is considerable work ahead with many uncertainties. At this critical time, we must come together as one united country and world to stop the spread and provide the best care possible for individuals who contract the virus and develop infection. A number of novel and repurposed therapies agents with activity against SARS-CoV-2 have been identified and most institutions have developed clinical pathways to operationalize their use in appropriate COVID-19 patients.<sup>1-3</sup> However, optimal drug therapy decisions for those with moderate to severe COVID-19 infections are extremely challenging at this time as evidence is limited.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Michigan</li><li>État de New York</li></region></list><tree><country name="États-Unis"><region name="État de New York"><name sortKey="Lodise, Thomas P" sort="Lodise, Thomas P" uniqKey="Lodise T" first="Thomas P" last="Lodise">Thomas P. Lodise</name></region><name sortKey="Rybak, Michael J" sort="Rybak, Michael J" uniqKey="Rybak M" first="Michael J" last="Rybak">Michael J. Rybak</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000273 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000273 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32267556
|texte= COVID-19: Important Therapy Considerations and Approaches in this Hour of Need.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32267556" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a MersV1
| This area was generated with Dilib version V0.6.33. |  |